Astellas, Medivation submit European Marketing Authorization Software for XTANDI capsules Astellas Pharma Inc. and Medivation Inc. XTANDI happens to be approved in Europe for the treating adult men with mCRPC whose disease has progressed on or after docetaxel chemotherapy. The European application is based on the outcomes from the Phase 3 PREVAIL trial analyzing XTANDI in comparison with placebo in more than 1,700 chemotherapy-naive mCRPC patients.In East Asia, the prevalence of myopia is considerably greater than in the West Asia, and appears to have a youthful starting point. In Japan, mCNV may be the second most common reason behind blindness. About the mCNV trial 3 out of four sufferers in the trial will obtain an injection of VEGF Trap-Eye in to the affected eyesight , and one out of four patients shall get a sham procedure. The clinical final result of both treatment groups after 24 weeks will end up being assessed by a different group of doctors who don’t realize what treatment the individuals received. From week 24 onward, sham sufferers may receive dynamic treatment.